Logo
Login
Subscribe
Oliver Buchannon
Ashar Dhana

⚡Tralokinumab for atopic hand eczema

Nov 29, 2025

•

9 min read

⚡Tralokinumab for atopic hand eczema

Ashar Dhana
Ashar Dhana
⚡Eczema trial tests bathing frequency

Nov 22, 2025

•

9 min read

⚡Eczema trial tests bathing frequency

Ashar Dhana
Ashar Dhana
⚡CAR T for autoimmune disease

Nov 15, 2025

•

10 min read

⚡CAR T for autoimmune disease

Ashar Dhana
Ashar Dhana
⚡Upadacitinib advances in vitiligo

Nov 8, 2025

•

11 min read

⚡Upadacitinib advances in vitiligo

Ashar Dhana
Ashar Dhana
⚡T-cell engager for immune reset

Nov 1, 2025

•

9 min read

⚡T-cell engager for immune reset

Ashar Dhana
Ashar Dhana
⚡One-year of remibrutinib in CSU

Oct 25, 2025

•

9 min read

⚡One-year of remibrutinib in CSU

Ashar Dhana
Ashar Dhana
⚡A first for high-risk cutaneous SCC

Oct 18, 2025

•

9 min read

⚡A first for high-risk cutaneous SCC

Ashar Dhana
Ashar Dhana
⚡Sonelokimab stumbles in pivotal HS trials

Oct 11, 2025

•

9 min read

⚡Sonelokimab stumbles in pivotal HS trials

Ashar Dhana
Ashar Dhana
⚡Three FDA dermatology approvals

Oct 4, 2025

•

10 min read

⚡Three FDA dermatology approvals

Ashar Dhana
Ashar Dhana
⚡Biggest updates from EADV 2025

Sep 27, 2025

•

11 min read

⚡Biggest updates from EADV 2025

Ashar Dhana
Ashar Dhana
⚡Landmark syphilis trial

Sep 20, 2025

•

9 min read

⚡Landmark syphilis trial

Ashar Dhana
Ashar Dhana
⚡Anti-OX40L falls short in eczema trial

Sep 13, 2025

•

9 min read

⚡Anti-OX40L falls short in eczema trial

Ashar Dhana
Ashar Dhana
⚡First 4-in-1 psoriasis trial in high impact sites

Sep 6, 2025

•

9 min read

⚡First 4-in-1 psoriasis trial in high impact sites

Ashar Dhana
Ashar Dhana
⚡New agent for dialysis-associated pruritus

Aug 30, 2025

•

10 min read

⚡New agent for dialysis-associated pruritus

Ashar Dhana
Ashar Dhana
⚡Anti-PD-1 win for desmoplastic melanoma

Aug 23, 2025

•

9 min read

⚡Anti-PD-1 win for desmoplastic melanoma

Ashar Dhana
Ashar Dhana
⚡First evidence β-HPV can cause cSCC

Aug 16, 2025

•

9 min read

⚡First evidence β-HPV can cause cSCC

Ashar Dhana
Ashar Dhana
⚡A first for chronic hand eczema

Aug 9, 2025

•

10 min read

⚡A first for chronic hand eczema

Ashar Dhana
Ashar Dhana
⚡New AI model for dermatology

Jul 26, 2025

•

10 min read

⚡New AI model for dermatology

Ashar Dhana
Ashar Dhana
⚡Next-generation TYK2 for psoriasis

Jul 19, 2025

•

10 min read

⚡Next-generation TYK2 for psoriasis

Ashar Dhana
Ashar Dhana
⚡New long acting IL13 antibody for eczema

Jul 12, 2025

•

10 min read

⚡New long acting IL13 antibody for eczema

Ashar Dhana
Ashar Dhana
⚡First-in-class Treg therapy for eczema

Jul 5, 2025

•

10 min read

⚡First-in-class Treg therapy for eczema

Ashar Dhana
Ashar Dhana
⚡First FDA-approved biologic for BP

Jun 28, 2025

•

10 min read

⚡First FDA-approved biologic for BP

Ashar Dhana
Ashar Dhana
⚡Anti-KIT in CSU, povorcitinib for vitiligo, and guselkumab in PsA

Jun 21, 2025

•

10 min read

⚡Anti-KIT in CSU, povorcitinib for vitiligo, and guselkumab in PsA

Ashar Dhana
Ashar Dhana
⚡First oral FASN inhibitor for acne

Jun 14, 2025

•

10 min read

⚡First oral FASN inhibitor for acne

Ashar Dhana
Ashar Dhana
⚡Two firsts in SCC, landmark Botox trial, and ucenprubart for AD

Jun 7, 2025

•

10 min read

⚡Two firsts in SCC, landmark Botox trial, and ucenprubart for AD

Ashar Dhana
Ashar Dhana
Load more

The 4mm

The most impactful dermatology news, curated by a dermatologist and delivered in a 5-minute weekly email. We scan 70+ sources so you don’t have to.

Home

Posts

© 2025 The 4mm.

Privacy policy

Terms of use

Powered by beehiiv